Welcome to our dedicated page for Phibro Animal Health Corporation news (Ticker: PAHC), a resource for investors and traders seeking the latest updates and insights on Phibro Animal Health Corporation stock.
Phibro Animal Health Corporation (Class A, symbol: PAHC) is a leading global company specializing in animal health and mineral nutrition. With over 40 years of experience, Phibro is dedicated to meeting the rising demand for animal protein by focusing solely on animals used in food production. The company offers a comprehensive range of products for poultry, swine, beef and dairy cattle, and aquaculture.
Phibro's core business involves the development, manufacturing, and marketing of products designed to prevent, control, and treat animal diseases, enhance nutrition, and contribute to balanced mineral nutrition. Their product portfolio includes antibacterials, anticoccidials, nutritional specialty products, and vaccines. The company's operations are divided into three segments: Animal Health, Mineral Nutrition, and Performance Products, with the Animal Health segment being the primary revenue driver.
In the fiscal year ending June 30, 2017, Phibro reported net sales of $764 million. The company employs over 1,400 professionals who are committed to delivering value-based solutions to livestock producers, helping them maintain and enhance the health of their animals. Phibro's products are sold both in the United States and internationally, demonstrating its significant global footprint.
Recent achievements and ongoing projects by Phibro include the development of new vaccines and nutritional specialties aimed at improving animal health and productivity. The company continues to partner with various stakeholders in the livestock industry to innovate and provide sustainable solutions.
Phibro's financial condition remains robust, supported by consistent revenue streams from its diversified product offerings. The company’s focus on research and development underscores its commitment to advancing animal health technologies and addressing the evolving needs of the livestock industry.
For the latest news and updates, Phibro Animal Health Corporation remains a key player in the animal health sector, reflecting its dedication to enhancing the well-being of food animals globally.
Phibro Animal Health Corporation (NASDAQ: PAHC) is set to announce its third quarter financial results on May 3, 2023, after market close. A conference call will follow on May 4, 2023, at 9:00 AM ET, accessible via phone or webcast. Interested parties can find the webcast on the company's investor relations page. Phibro aims to provide solutions for animal health and nutrition, enhancing the well-being of livestock and companion animals. More details about the results will be made available during the call, along with insights into the company's performance and future outlook.
Phibro Animal Health Corporation (NASDAQ: PAHC) will participate in the Bank of America Securities 2023 Health Care Conference on May 9, 2023, at 4:20 PM PDT. Chief Financial Officer Damian Finio will present to financial analysts and investors. The live audio presentation can be accessed on the company’s Investor Relations website, with a replay and archived session available thereafter.
Phibro is a global leader in animal health and mineral nutrition, dedicated to supporting livestock producers, veterinarians, and consumers in enhancing animal health. For more information, visit www.pahc.com.
Phibro Animal Health Corporation (NASDAQ: PAHC) will participate in the Barclays Global Healthcare Conference on March 15, 2023, at 10:45 AM ET. CFO Damian Finio will present to financial analysts and investors at the Loews Miami Beach Hotel. A live audio presentation will be available on the company's Investor Relations Website, with a replay to follow. Phibro is recognized as a leader in animal health and mineral nutrition, supporting livestock producers and veterinarians in enhancing animal wellbeing.
Phibro Animal Health Corporation (NASDAQ:PAHC) will participate in the Bank of America 2023 Virtual Animal Health Summit on Thursday, March 2, 2023, at 10:50 AM ET. Chief Financial Officer Damian Finio and Executive Vice President, Corporate Strategy Daniel Bendheim will address financial analysts and investors during this event. The live audio presentation can be accessed on the company's Investor Relations Website, with a replay available afterwards. Phibro is a global leader in animal health and mineral nutrition, dedicated to enhancing the health of farm and companion animals.
Phibro Animal Health Corporation (Nasdaq: PAHC) reported its second-quarter financial results for the period ending December 31, 2022. Net sales increased 5% to $244.6 million, while net income fell 59% to $7.2 million, resulting in diluted EPS of $0.18. Adjusted EBITDA rose 6% to $30.9 million. The Animal Health segment saw a 9% sales increase, offset by an 8% decline in Mineral Nutrition. SG&A expenses surged 27% due to environmental remediation costs. The company updated its FY2023 guidance, lowering net income and diluted EPS forecasts but maintaining sales and adjusted EBITDA projections.
Phibro Animal Health Corporation (NASDAQ: PAHC) has appointed Alejandro Bernal as a Class III director, effective immediately, increasing the Board membership to nine, with six independent directors. Bernal, CEO of PetDx and former President of Mars Veterinary Health, brings extensive experience in the animal health sector. Additionally, the Board declared a quarterly cash dividend of $0.12 per share on Class A and Class B common stock, payable on March 22, 2023, to shareholders of record by March 1, 2023.
Phibro Animal Health Corporation (NASDAQ: PAHC) will report its second quarter financial results on February 8, 2023, following the market's close. A conference call will be held on February 9, 2023, at 9:00 AM ET, giving interested parties access via a live webcast or by calling in. This provides an opportunity for investors to gain insights into the company's financial health and future outlook. For more details, visit Phibro's investor relations page.
Phibro Animal Health Corporation (Nasdaq: PAHC) reported its financial results for Q1 2023, ending September 30, 2022. Net sales reached $232.5 million, an 8% increase year-over-year, driven mainly by Animal Health and Mineral Nutrition segments. However, net income fell 41% to $3.9 million, with diluted EPS dropping to $0.10. Adjusted EBITDA slightly declined to $22.1 million. The company reiterated guidance for net sales but revised forecasts for net income and EPS, reflecting increased interest rates and changes in tax legislation.
FAQ
What is the current stock price of Phibro Animal Health Corporation (PAHC)?
What is the market cap of Phibro Animal Health Corporation (PAHC)?
What does Phibro Animal Health Corporation do?
Which animals does Phibro's products cater to?
What are the main product categories of Phibro Animal Health Corporation?
How many employees does Phibro Animal Health Corporation have?
How much revenue did Phibro report for the fiscal year ending June 30, 2017?
What are the primary segments of Phibro's operations?
Where does Phibro sell its products?
What recent projects is Phibro involved in?
Who are Phibro's primary customers?
What drives Phibro's revenue?
